Ron-Hwa Lin, Ph.D.

Ron-Hwa Lin, Ph.D. CEO and Chairman of the Board, Abgenomics, Taiwan. Founded in 2000, AbGenomics Corporation is a biopharmaceutical company focusing on the discovery and development of novel therapeutic monoclonal antibodies for the treatment of inflammatory diseases and cancer. Abgenomics' significant product pipeline has attracted attention of major international pharmaceutical companies. For example, Boehringer Ingelheim recently signed an exclusive licensing agreement with Abgenomics to develop, manufacture and commercialize products resulting from its antibody 168.

Dr. Lin is currently a member of the Editorial Board for Int. Immunopharmacology (2001 - now) and served as Associate Editor for Journal of Biomedical Science (1998 - 2002).

Prior to joining AbGenomics, Dr. Lin was Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin received his Diplom (Apply Microbiology/biotechnology) and Dr. rer. nat. (Immunology) degrees from the University of Tubingen in Germany. He completed his Diplom thesis at the Max Planck Institute for Immunogenetic in Germany and doctoral training at the Basel Institute for Immunology in Switzerland and his postdoctoral fellowship in Immunobiology at Howard Hughes Medical Institute of Yale University.